Cadène M, Boudier C, de Marcillac G D, Bieth J G
Laboratoire d'Enzymologie, INSERM Unité 392, Université Louis Pasteur de Strasbourg, Illkirch, France.
J Biol Chem. 1995 Jun 2;270(22):13204-9. doi: 10.1074/jbc.270.22.13204.
Commercial low molecular mass heparin accelerates the inhibition of neutrophil elastase by mucus proteinase inhibitor, the predominant antielastase of lung secretions (Faller, B., Mély, Y., Gérard, D., and Bieth, J.G. (1992) Biochemistry 31, 8285-8290). To study the kinetic mechanism of this rate enhancement, we have isolated a 4.5-kDa heparin fragment from commercial heparin. This compound is fairly monodisperse as shown by analytical ultracentrifugation. It binds elastase and inhibitor with a 1:1 stoichiometry and an equilibrium dissociation constant of 3 and 210 nM, respectively. It also forms a tight complex with EI. Flow calorimetry shows that the inhibitor-heparin interaction is characterized by a large negative enthalpy change (delta H0 = -45.2 kJ mol-1) and a small entropy change (delta S = -23.7 J K-1 mol-1). Stopped-flow kinetics run under pseudo-first-order conditions ([Io] >> [Eo]) show that in the absence of heparin the inhibition conforms to a simple bimolecular reaction, [formula: see text] where, ka = 3.1 x 10(6) M-1 s-1, kd = 10(-4) s-1, and Ki = 33 pM, whereas in the presence of heparin, E and I react via a two-step mechanism, [formula: see text] where Ki* = 86 nM, k2 = 2.2 s-1, k-2 = 10(-3) s-1, and Ki = 37 pM. Thus, heparin increases both the rate of inhibition by promoting the formation of a high affinity EI* intermediate and the rate of EI dissociation. Since the dissociation is negligible in bronchial secretions where the inhibitor concentration is much higher than Ki, it may be concluded that heparin significantly potentiates the inhibitor's antielastase potential in vivo.
商业低分子量肝素可加速黏液蛋白酶抑制剂对中性粒细胞弹性蛋白酶的抑制作用,黏液蛋白酶抑制剂是肺分泌物中主要的抗弹性蛋白酶(法勒,B.,梅利,Y.,热拉尔,D.,以及比耶,J.G.(1992年)《生物化学》31卷,8285 - 8290页)。为了研究这种速率增强的动力学机制,我们从商业肝素中分离出了一个4.5 kDa的肝素片段。如分析超速离心所示,该化合物相当均一。它以1:1的化学计量比与弹性蛋白酶和抑制剂结合,平衡解离常数分别为3 nM和210 nM。它还与EI形成紧密复合物。流动量热法表明,抑制剂 - 肝素相互作用的特征是焓变大幅为负(ΔH0 = -45.2 kJ·mol⁻¹)且熵变较小(ΔS = -23.7 J·K⁻¹·mol⁻¹)。在准一级条件([Io] >> [Eo])下进行的停流动力学表明,在没有肝素的情况下,抑制作用符合简单的双分子反应,[公式:见原文],其中,ka = 3.1×10⁶ M⁻¹·s⁻¹,kd = 10⁻⁴ s⁻¹,且Ki = 33 pM,而在有肝素的情况下,E和I通过两步机制反应,[公式:见原文],其中Ki* = 86 nM,k2 = 2.2 s⁻¹,k⁻² = 10⁻³ s⁻¹,且Ki = 37 pM。因此,肝素通过促进高亲和力EI*中间体的形成以及EI解离速率,提高了抑制速率。由于在抑制剂浓度远高于Ki的支气管分泌物中解离可忽略不计,所以可以得出结论,肝素在体内显著增强了抑制剂的抗弹性蛋白酶潜力。